Ophthalmic Drugs Market by Indication (Dry Eye, Glaucoma, Infection/Inflammation/Allergy, Retinal Disorders, and Others), Type (Prescription Drugs and Over-the-counter-Drugs), Dosage Form (Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semi-Solid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, and Other Ophthalmic Drug Forms), Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies and Others), and Therapeutic Class (Anti-Glaucoma, Anti-infection, Anti-inflammation, Anti-allergy, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027
The global ophthalmic drugs market was valued at $36,488.48 million in 2019, and is estimated to reach $58,134.92 million by 2027, registering a CAGR of 5.6% from 2020 to 2027. The eye is one of the most sensitive organ of the human body. Ophthalmic drugs are the formulations that are designed for the treatment of eye diseases such as cataract, glaucoma, color blindness, diabetic macular edema, cytomegalovirus (CMV) retinitis, and age-related macular degeneration.
Growth of the global ophthalmic drugs market is majorly driven by a rise in geriatric population; alarming increase in the prevalence of eye disease such as glaucoma, cataract, retinal disease and muscular disease; and a surge in demand for ophthalmic drug for treatment of eye disease. For instance, according to the World Health Organization (WHO), in 2021, approximately 2.2 billion population was diagnosed with vision impairment across the globe. As per the statistics, the major cause of blindness and vision loss are cataracts and untreated refractive error for a longer period of time. Moreover, the geriatric population is more vulnerable to eye diseases due to aging effect the lens of eye become less flexible and decrease the ability to focus on an object. For instance, as per the data published by UN, 962 million population were present above the age of 60 years in 2017 which is expected to get double to nearly 2.1 billion by the year of 2050. It has been observed from the report of the American Academy of Ophthalmology, that there were 64.3 million people suffered from glaucoma in 2013, which increased to 76.0 million in 2020 and is expected to rise to 111.8 million by 2040. Thus, the rise in the geriatric population and increase in prevalence of glaucoma is expected to propel the demand for ophthalmic drugs, which, in turn, augments the market growth.
Furthermore, ophthalmic drugs play an important role in the global healthcare sector. Manufacturing of different dosage form of ophthalmic drugs such as drops, gel, and ointment is used for the treatment of a wide range of eye diseases. Moreover, rise in investment and activities in R&D by various healthcare sectors for development of new ophthalmic drugs, such as REFRESH DIGITAL lubricant eye drop (AbbVie Inc.) and CEQUA (Sun Pharmaceutical Ltd.), drive the growth of the global market. Upsurge in investment in R&D sector is a strategy of venture for the development of novel products and further aids to support the long-term growth of the business. In addition, rise in adoption of new technology is expected to provide lucrative opportunity for the expansion of the ophthalmic drugs market growth. For instance, in June 2020, Senju Pharmaceutical and Otsuka Pharmaceutical launched AILAMIDE, which is a novel combination ophthalmic solution used for treatment of glaucoma and ocular hypertension.
On the contrary, side effects associated with ophthalmic drugs and prolonged timelines for the development of efficient ophthalmic formulations is anticipated to hinder the market growth during the forecast period. For instance, Xalatan, which is prescribed for treatment of glaucoma, can also cause blurred vision, dry eye, and darkening of the eyelid. Moreover, the factors such as choice of excipients, buffers, maintaining the ideal pH and thickening agents lead to prolonged timelines for the development of ophthalmic drugs.
The ophthalmic drugs market is segmented into indication, type, dosage form, distribution channel, therapeutic class, and region. Depending on indication, the market is segmented into dry eye, glaucoma, infection/inflammation/allergy, retinal disorder, and others. The retinal disease segment is further classified into wet age-related macular degeneration, dry age-related macular degeneration, diabetic retinopathy, and others.
On the basis of type, the market is fragmented into the prescription drugs and over-the-counter-drugs. By dosage form, it is differentiated into liquid ophthalmic drug forms, solid ophthalmic drug forms, semi-solid ophthalmic drug forms, multicompartment drug delivery systems, and other ophthalmic drug forms. As per distribution channel, the market is classified into hospital pharmacies, drug stores, online pharmacies, and others. By therapeutic class, the global market is segregated into anti-glaucoma, anti-infection, anti-inflammation, anti-allergy, and others. On regional level, the ophthalmic drugs market is analyzed across North America, Europe, Asia-Pacific, Middle East, North-Africa, and Rest of World.
KEY BENEFITS FOR STAKEHOLDERS
By Indication
Growth of the global ophthalmic drugs market is majorly driven by a rise in geriatric population; alarming increase in the prevalence of eye disease such as glaucoma, cataract, retinal disease and muscular disease; and a surge in demand for ophthalmic drug for treatment of eye disease. For instance, according to the World Health Organization (WHO), in 2021, approximately 2.2 billion population was diagnosed with vision impairment across the globe. As per the statistics, the major cause of blindness and vision loss are cataracts and untreated refractive error for a longer period of time. Moreover, the geriatric population is more vulnerable to eye diseases due to aging effect the lens of eye become less flexible and decrease the ability to focus on an object. For instance, as per the data published by UN, 962 million population were present above the age of 60 years in 2017 which is expected to get double to nearly 2.1 billion by the year of 2050. It has been observed from the report of the American Academy of Ophthalmology, that there were 64.3 million people suffered from glaucoma in 2013, which increased to 76.0 million in 2020 and is expected to rise to 111.8 million by 2040. Thus, the rise in the geriatric population and increase in prevalence of glaucoma is expected to propel the demand for ophthalmic drugs, which, in turn, augments the market growth.
Furthermore, ophthalmic drugs play an important role in the global healthcare sector. Manufacturing of different dosage form of ophthalmic drugs such as drops, gel, and ointment is used for the treatment of a wide range of eye diseases. Moreover, rise in investment and activities in R&D by various healthcare sectors for development of new ophthalmic drugs, such as REFRESH DIGITAL lubricant eye drop (AbbVie Inc.) and CEQUA (Sun Pharmaceutical Ltd.), drive the growth of the global market. Upsurge in investment in R&D sector is a strategy of venture for the development of novel products and further aids to support the long-term growth of the business. In addition, rise in adoption of new technology is expected to provide lucrative opportunity for the expansion of the ophthalmic drugs market growth. For instance, in June 2020, Senju Pharmaceutical and Otsuka Pharmaceutical launched AILAMIDE, which is a novel combination ophthalmic solution used for treatment of glaucoma and ocular hypertension.
On the contrary, side effects associated with ophthalmic drugs and prolonged timelines for the development of efficient ophthalmic formulations is anticipated to hinder the market growth during the forecast period. For instance, Xalatan, which is prescribed for treatment of glaucoma, can also cause blurred vision, dry eye, and darkening of the eyelid. Moreover, the factors such as choice of excipients, buffers, maintaining the ideal pH and thickening agents lead to prolonged timelines for the development of ophthalmic drugs.
The ophthalmic drugs market is segmented into indication, type, dosage form, distribution channel, therapeutic class, and region. Depending on indication, the market is segmented into dry eye, glaucoma, infection/inflammation/allergy, retinal disorder, and others. The retinal disease segment is further classified into wet age-related macular degeneration, dry age-related macular degeneration, diabetic retinopathy, and others.
On the basis of type, the market is fragmented into the prescription drugs and over-the-counter-drugs. By dosage form, it is differentiated into liquid ophthalmic drug forms, solid ophthalmic drug forms, semi-solid ophthalmic drug forms, multicompartment drug delivery systems, and other ophthalmic drug forms. As per distribution channel, the market is classified into hospital pharmacies, drug stores, online pharmacies, and others. By therapeutic class, the global market is segregated into anti-glaucoma, anti-infection, anti-inflammation, anti-allergy, and others. On regional level, the ophthalmic drugs market is analyzed across North America, Europe, Asia-Pacific, Middle East, North-Africa, and Rest of World.
KEY BENEFITS FOR STAKEHOLDERS
- The report provides an in-depth analysis of the global ophthalmic drugs market size along with the current trends and future estimations to elucidate the imminent investment pockets
- It offers market analysis from 2020 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market
- A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global ophthalmic drugs market
By Indication
- Dry Eye
- Glaucoma
- Infection/Inflammation/Allergy
- Retinal Disorders
- Wet Age-related Macular Degeneration
- Dry Age-related Macular Degeneration
- Diabetic Retinopathy
- Others
- Others
- Prescription Drugs
- Over-the-counter Drugs
- Liquid Ophthalmic Drug Forms
- Solid Ophthalmic Drug Forms
- Semisolid Ophthalmic Drug Forms
- Multicompartment Drug Delivery Systems
- Other Ophthalmic Drug Forms
- Hospital Pharmacies
- Drug Stores
- Online Pharmacies
- Others
- Anti-glaucoma
- Anti-infection
- Anti-inflammation
- Anti-allergy
- Others
- North America
- U.S.
- Rest of North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Poland
- Rest of Europe
- Asia-Pacific
- Malaysia
- Vietnam
- Thailand
- Philippines
- Rest of Asia-Pacific
- Middle East
- UAE
- South Arabia
- Palestine
- Jordan
- Bahrain
- Qatar
- Azerbaijan
- Georgia
- Iraq
- Pakistan
- Kuwait
- Israel
- Kazakhstan
- Uzbekistan
- Tajikistan
- Kyrgyzstan
- Turkmenistan
- Rest of Middle East
- North Africa
- Egypt
- Morocco
- Tunisia
- Algeria
- Lybia
- Rest of North Africa
- Rest of World
- Brazil
- Others
- AbbVie Inc. (Allergan plc)
- Alcon Inc.
- Bausch & Lomb Incorporated
- F. Hoffmann-La Roche Ltd (Genentech, Inc.)
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Santen Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd. (Actavis Generics)
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Top player positioning, 2019
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in prevalence of ophthalmic disorders
3.5.1.2.Advancements in research and development in optometry
3.5.1.3.Growth in geriatric population
3.5.1.4.Increase in demand for the ophthalmic drugs
3.5.2.Restraints
3.5.2.1.Risks associated with ophthalmic drugs
3.5.2.2.Longer timeline required for the formulation of ophthalmic drugs
3.5.3.Opportunity
3.5.3.1.Increase in research and developments by major key players
3.5.4.Impact analysis
3.6.Impact analysis of COVID-19 on the Ophthalmic Drug market
CHAPTER 4:OPHTHALMIC DRUGS MARKET, BY INDICATION
4.1.Overview
4.1.1.Market size and forecast
4.2.Dry Eye
4.2.1.Market size and forecast, by region
4.2.2.Market analysis, by country
4.2.3.Market size and forecast, by dosage form
4.3.Glaucoma
4.3.1.Market size and forecast, by region
4.3.2.Market analysis, by country
4.3.3.Market size and forecast, by dosage form
4.4.Infection/Inflammation/Allergy
4.4.1.Market size and forecast, by region
4.4.2.Market analysis, by country
4.4.3.Market size and forecast, by dosage form
4.5.Retinal Disorders
4.5.1.Market size and forecast, by type
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
4.5.4.Market size and forecast, by dosage form
4.5.5.Wet age-related macular degeneration
4.5.5.1.Market size and forecast, by dosage form
4.5.6.Dry age-related macular degeneration
4.5.6.1.Market size and forecast, by dosage form
4.5.7.Diabetic retinopathy
4.5.7.1.Market size and forecast, by dosage form
4.5.8.Other Retinal Disorders
4.5.8.1.Market size and forecast, by dosage form
4.6.Others
4.6.1.Market size and forecast, by region
4.6.2.Market analysis, by country
4.6.3.Market size and forecast, by dosage form
CHAPTER 5:OPHTHALMIC DRUGS MARKET, BY TYPE
5.1.Overview
5.1.1.Market size and forecast
5.2.Prescription Drugs
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.2.3.Market size and forecast, by dosage form
5.3.Over-The-Counter-Drugs
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.3.3.Market size and forecast, by dosage form
CHAPTER 6:OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM
6.1.Overview
6.1.1.Market size and forecast
6.2.Liquid ophthalmic drug forms
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Solid ophthalmic drug forms
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Semisolid ophthalmic drug forms
6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country
6.5.Multicompartment drug delivery systems
6.5.1.Market size and forecast, by region
6.5.2.Market analysis, by country
6.6.Other ophthalmic drug forms
6.6.1.Market size and forecast, by region
6.6.2.Market analysis, by country
6.7.Dry Eye
6.7.1.Market size and forecast, by region
6.7.2.Market analysis, by country
6.7.3.Market size and forecast, by dosage form
6.8.Glaucoma
6.8.1.Market size and forecast, by region
6.8.2.Market analysis, by country
6.8.3.Market size and forecast, by dosage form
6.9.Infection/Inflammation/Allergy
6.9.1.Market size and forecast, by region
6.9.2.Market analysis, by country
6.9.3.Market size and forecast, by dosage form
6.10.Retinal Disorders
6.10.1.Market size and forecast, by type
6.10.2.Market size and forecast, by region
6.10.3.Market analysis, by country
6.10.4.Market size and forecast, by dosage form
6.10.5.Wet age-related macular degeneration
6.10.5.1.Market size and forecast, by dosage form
6.10.6.Dry age-related macular degeneration
6.10.6.1.Market size and forecast, by dosage form
6.10.7.Diabetic retinopathy
6.10.7.1.Market size and forecast, by dosage form
6.10.8.Other Retinal Disorders
6.10.8.1.Market size and forecast, by dosage form
6.11.Others
6.11.1.Market size and forecast, by region
6.11.2.Market analysis, by country
6.11.3.Market size and forecast, by dosage form
CHAPTER 7:OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
7.1.Overview
7.1.1.Market size and forecast
7.2.Hospital Pharmacies
7.2.1.Market size and forecast, by region
7.2.2.Market analysis, by country
7.2.3.Market size and forecast, by dosage form
7.3.Drug Stores
7.3.1.Market size and forecast, by region
7.3.2.Market analysis, by country
7.3.3.Market size and forecast, by dosage form
7.4.Online Pharmacies
7.4.1.Market size and forecast, by region
7.4.2.Market analysis, by country
7.4.3.Market size and forecast, by dosage form
7.5.Others
7.5.1.Market size and forecast, by region
7.5.2.Market analysis, by country
7.5.3.Market size and forecast, by dosage form
CHAPTER 8:OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS
8.1.Overview
8.1.1.Market size and forecast
8.2.Anti-Glaucoma
8.2.1.Market size and forecast, by region
8.2.2.Market analysis, by country
8.2.3.Market size and forecast, by dosage form
8.3.Anti-infection
8.3.1.Market size and forecast, by region
8.3.2.Market analysis, by country
8.3.3.Market size and forecast, by dosage form
8.4.Anti-inflammatory
8.4.1.Market size and forecast, by region
8.4.2.Market analysis, by country
8.4.3.Market size and forecast, by dosage form
8.5.Anti-allergy
8.5.1.Market size and forecast, by region
8.5.2.Market analysis, by country
8.5.3.Market size and forecast, by dosage form
8.6.Others
8.6.1.Market size and forecast, by region
8.6.2.Market analysis, by country
8.6.3.Market size and forecast, by dosage form
CHAPTER 9:OPHTHALMIC DRUGS MARKET, BY REGION
9.1.Overview
9.1.1.Market size and forecast
9.2.North America
9.2.1.North America market size and forecast, by indication
9.2.2.North America market size and forecast, by type
9.2.3.North America market size and forecast, by dosage form
9.2.4.North America market size and forecast, by distribution channel
9.2.5.North America market size and forecast, by therapeutic class
9.2.6.North America market size and forecast, by country
9.2.7.U.S.
9.2.7.1.U.S. market size and forecast, by indication
9.2.7.2.U.S. market size and forecast, by type
9.2.7.3.U.S. market size and forecast, by dosage form
9.2.7.4.U.S. market size and forecast, by distribution channel
9.2.7.5.U.S. market size and forecast, by therapeutic class
9.2.8.Rest of North America
9.2.8.1.Rest of North America market size and forecast, by indication
9.2.8.2.Rest of North America market size and forecast, by type
9.2.8.3.Rest of North America market size and forecast, by dosage form
9.2.8.4.Rest of North America market size and forecast, by distribution channel
9.2.8.5.Rest of North America market size and forecast, by therapeutic class
9.3.Europe
9.3.1.Europe market size and forecast, by indication
9.3.2.Europe market size and forecast, by type
9.3.3.Europe market size and forecast, by dosage form
9.3.4.Europe market size and forecast, by distribution channel
9.3.5.Europe market size and forecast, by therapeutic class
9.3.6.Europe market size and forecast, by country
9.3.7.Germany
9.3.7.1.Germany market size and forecast, by indication
9.3.7.2.Germany market size and forecast, by type
9.3.7.3.Germany market size and forecast, by dosage form
9.3.7.4.Germany market size and forecast, by distribution channel
9.3.7.5.Germany market size and forecast, by therapeutic class
9.3.8.France
9.3.8.1.France market size and forecast, by indication
9.3.8.2.France market size and forecast, by type
9.3.8.3.France market size and forecast, by dosage form
9.3.8.4.France market size and forecast, by distribution channel
9.3.8.5.France market size and forecast, by therapeutic class
9.3.9.UK
9.3.9.1.UK market size and forecast, by indication
9.3.9.2.UK market size and forecast, by type
9.3.9.3.UK market size and forecast, by dosage form
9.3.9.4.UK market size and forecast, by distribution channel
9.3.9.5.UK market size and forecast, by therapeutic class
9.3.10.Italy
9.3.10.1.Italy market size and forecast, by indication
9.3.10.2.Italy market size and forecast, by type
9.3.10.3.Italy market size and forecast, by dosage form
9.3.10.4.Italy market size and forecast, by distribution channel
9.3.10.5.Italy market size and forecast, by therapeutic class
9.3.11.Spain
9.3.11.1.Spain market size and forecast, by indication
9.3.11.2.Spain market size and forecast, by type
9.3.11.3.Spain market size and forecast, by dosage form
9.3.11.4.Spain market size and forecast, by distribution channel
9.3.11.5.Spain market size and forecast, by therapeutic class
9.3.12.Poland
9.3.12.1.Poland market size and forecast, by indication
9.3.12.2.Poland market size and forecast, by type
9.3.12.3.Poland market size and forecast, by dosage form
9.3.12.4.Poland market size and forecast, by distribution channel
9.3.12.5.Poland market size and forecast, by therapeutic class
9.3.13.Rest of Europe
9.3.13.1.Rest of Europe market size and forecast, by indication
9.3.13.2.Rest of Europe market size and forecast, by type
9.3.13.3.Rest of Europe market size and forecast, by dosage form
9.3.13.4.Rest of Europe market size and forecast, by distribution channel
9.3.13.5.Rest of Europe market size and forecast, by therapeutic class
9.4.Asia-Pacific
9.4.1.Asia-Pacific market size and forecast, by indication
9.4.2.Asia-Pacific market size and forecast, by type
9.4.3.Asia-Pacific market size and forecast, by dosage form
9.4.4.Asia-Pacific market size and forecast, by distribution channel
9.4.5.Asia-Pacific market size and forecast, by therapeutic class
9.4.6.Asia-Pacific market size and forecast, by country
9.4.7.Malaysia
9.4.7.1.Malaysia market size and forecast, by indication
9.4.7.2.Malaysia market size and forecast, by type
9.4.7.3.Malaysia market size and forecast, by dosage form
9.4.7.4.Malaysia market size and forecast, by distribution channel
9.4.7.5.Malaysia market size and forecast, by therapeutic class
9.4.8.Vietnam
9.4.8.1.Vietnam market size and forecast, by indication
9.4.8.2.Vietnam market size and forecast, by type
9.4.8.3.Vietnam market size and forecast, by dosage form
9.4.8.4.Vietnam market size and forecast, by distribution channel
9.4.8.5.Vietnam market size and forecast, by therapeutic class
9.4.9.Thailand
9.4.9.1.Thailand market size and forecast, by indication
9.4.9.2.Thailand market size and forecast, by type
9.4.9.3.Thailand market size and forecast, by dosage form
9.4.9.4.Thailand market size and forecast, by distribution channel
9.4.9.5.Thailand market size and forecast, by therapeutic class
9.4.10.Philippines
9.4.10.1.Philippines market size and forecast, by indication
9.4.10.2.Philippines market size and forecast, by type
9.4.10.3.Philippines market size and forecast, by dosage form
9.4.10.4.Philippines market size and forecast, by distribution channel
9.4.10.5.Philippines market size and forecast, by therapeutic class
9.4.11.Rest of Asia-Pacific
9.4.11.1.Rest of Asia-Pacific market size and forecast, by indication
9.4.11.2.Rest of Asia-Pacific market size and forecast, by type
9.4.11.3.Rest of Asia-Pacific market size and forecast, by dosage form
9.4.11.4.Rest of Asia-Pacific market size and forecast, by distribution channel
9.4.11.5.Rest of Asia-Pacific market size and forecast, by therapeutic class
9.5.Middle East
9.5.1.Middle East market size and forecast, by indication
9.5.2.Middle East market size and forecast, by type
9.5.3.Middle East market size and forecast, by dosage form
9.5.4.Middle East market size and forecast, by distribution channel
9.5.5.Middle East market size and forecast, by therapeutic class
9.5.6.Middle East market size and forecast, by country
9.5.7.UAE
9.5.7.1.UAE market size and forecast, by indication
9.5.7.2.UAE market size and forecast, by type
9.5.7.3.UAE market size and forecast, by dosage form
9.5.7.4.UAE market size and forecast, by distribution channel
9.5.7.5.UAE market size and forecast, by therapeutic class
9.5.8.Saudi Arabia
9.5.8.1.Saudi Arabia market size and forecast, by indication
9.5.8.2.Saudi Arabia market size and forecast, by type
9.5.8.3.Saudi Arabia market size and forecast, by dosage form
9.5.8.4.Saudi Arabia market size and forecast, by distribution channel
9.5.8.5.Saudi Arabia market size and forecast, by therapeutic class
9.5.9.Palestine
9.5.9.1.Palestine market size and forecast, by indication
9.5.9.2.Palestine market size and forecast, by type
9.5.9.3.Palestine market size and forecast, by dosage form
9.5.9.4.Palestine market size and forecast, by distribution channel
9.5.9.5.Palestine market size and forecast, by therapeutic class
9.5.10.Jordan
9.5.10.1.Jordan market size and forecast, by indication
9.5.10.2.Jordan market size and forecast, by type
9.5.10.3.Jordan market size and forecast, by dosage form
9.5.10.4.Jordan market size and forecast, by distribution channel
9.5.10.5.Jordan market size and forecast, by therapeutic class
9.5.11.Bahrain
9.5.11.1.Bahrain market size and forecast, by indication
9.5.11.2.Bahrain market size and forecast, by type
9.5.11.3.Bahrain market size and forecast, by dosage form
9.5.11.4.Bahrain market size and forecast, by distribution channel
9.5.11.5.Bahrain market size and forecast, by therapeutic class
9.5.12.Qatar
9.5.12.1.Qatar market size and forecast, by indication
9.5.12.2.Qatar market size and forecast, by type
9.5.12.3.Qatar market size and forecast, by dosage form
9.5.12.4.Qatar market size and forecast, by distribution channel
9.5.12.5.Qatar market size and forecast, by therapeutic class
9.5.13.Azerbaijan
9.5.13.1.Azerbaijan market size and forecast, by indication
9.5.13.2.Azerbaijan market size and forecast, by type
9.5.13.3.Azerbaijan market size and forecast, by dosage form
9.5.13.4.Azerbaijan market size and forecast, by distribution channel
9.5.13.5.Azerbaijan market size and forecast, by therapeutic class
9.5.14.Georgia
9.5.14.1.Georgia market size and forecast, by indication
9.5.14.2.Georgia market size and forecast, by type
9.5.14.3.Georgia market size and forecast, by dosage form
9.5.14.4.Georgia market size and forecast, by distribution channel
9.5.14.5.Georgia market size and forecast, by therapeutic class
9.5.15.Iraq
9.5.15.1.Iraq market size and forecast, by indication
9.5.15.2.Iraq market size and forecast, by type
9.5.15.3.Iraq market size and forecast, by dosage form
9.5.15.4.Iraq market size and forecast, by distribution channel
9.5.15.5.Iraq market size and forecast, by therapeutic class
9.5.16.Pakistan
9.5.16.1.Pakistan market size and forecast, by indication
9.5.16.2.Pakistan market size and forecast, by type
9.5.16.3.Pakistan market size and forecast, by dosage form
9.5.16.4.Pakistan market size and forecast, by distribution channel
9.5.16.5.Pakistan market size and forecast, by therapeutic class
9.5.17.Kuwait
9.5.17.1.Kuwait market size and forecast, by indication
9.5.17.2.Kuwait market size and forecast, by type
9.5.17.3.Kuwait market size and forecast, by dosage form
9.5.17.4.Kuwait market size and forecast, by distribution channel
9.5.17.5.Kuwait market size and forecast, by therapeutic class
9.5.18.Israel
9.5.18.1.Israel market size and forecast, by indication
9.5.18.2.Israel market size and forecast, by type
9.5.18.3.Israel market size and forecast, by dosage form
9.5.18.4.Israel market size and forecast, by distribution channel
9.5.18.5.Israel market size and forecast, by therapeutic class
9.5.19.Kazakhstan
9.5.19.1.Kazakhstan market size and forecast, by indication
9.5.19.2.Kazakhstan market size and forecast, by type
9.5.19.3.Kazakhstan market size and forecast, by dosage form
9.5.19.4.Kazakhstan market size and forecast, by distribution channel
9.5.19.5.Kazakhstan market size and forecast, by therapeutic class
9.5.20.Uzbekistan
9.5.20.1.Uzbekistan market size and forecast, by indication
9.5.20.2.Uzbekistan market size and forecast, by type
9.5.20.3.Uzbekistan market size and forecast, by dosage form
9.5.20.4.Uzbekistan market size and forecast, by distribution channel
9.5.20.5.Uzbekistan market size and forecast, by therapeutic class
9.5.21.Tajikistan
9.5.21.1.Tajikistan market size and forecast, by indication
9.5.21.2.Tajikistan market size and forecast, by type
9.5.21.3.Tajikistan market size and forecast, by dosage form
9.5.21.4.Tajikistan market size and forecast, by distribution channel
9.5.21.5.Tajikistan market size and forecast, by therapeutic class
9.5.22.Kyrgyzstan
9.5.22.1.Kyrgyzstan market size and forecast, by indication
9.5.22.2.Kyrgyzstan market size and forecast, by type
9.5.22.3.Kyrgyzstan market size and forecast, by dosage form
9.5.22.4.Kyrgyzstan market size and forecast, by distribution channel
9.5.22.5.Kyrgyzstan market size and forecast, by therapeutic class
9.5.23.Turkmenistan
9.5.23.1.Turkmenistan market size and forecast, by indication
9.5.23.2.Turkmenistan market size and forecast, by type
9.5.23.3.Turkmenistan market size and forecast, by dosage form
9.5.23.4.Turkmenistan market size and forecast, by distribution channel
9.5.23.5.Turkmenistan market size and forecast, by therapeutic class
9.5.24.Rest of Middle East
9.5.24.1.Rest of Middle East market size and forecast, by indication
9.5.24.2.Rest of Middle East market size and forecast, by type
9.5.24.3.Rest of Middle East market size and forecast, by dosage form
9.5.24.4.Rest of Middle East market size and forecast, by distribution channel
9.5.24.5.Rest of Middle East market size and forecast, by therapeutic class
9.6.North Africa
9.6.1.North Africa market size and forecast, by indication
9.6.2.North Africa market size and forecast, by type
9.6.3.North Africa market size and forecast, by dosage form
9.6.4.North Africa market size and forecast, by distribution channel
9.6.5.North Africa market size and forecast, by therapeutic class
9.6.6.North Africa market size and forecast, by country
9.6.7.Egypt
9.6.7.1.Egypt market size and forecast, by indication
9.6.7.2.Egypt market size and forecast, by type
9.6.7.3.Egypt market size and forecast, by dosage form
9.6.7.4.Egypt market size and forecast, by distribution channel
9.6.7.5.Egypt market size and forecast, by therapeutic class
9.6.8.Morocco
9.6.8.1.Morocco market size and forecast, by indication
9.6.8.2.Morocco market size and forecast, by type
9.6.8.3.Morocco market size and forecast, by dosage form
9.6.8.4.Morocco market size and forecast, by distribution channel
9.6.8.5.Morocco market size and forecast, by therapeutic class
9.6.9.Tunisia
9.6.9.1.Tunisia market size and forecast, by indication
9.6.9.2.Tunisia market size and forecast, by type
9.6.9.3.Tunisia market size and forecast, by dosage form
9.6.9.4.Tunisia market size and forecast, by distribution channel
9.6.9.5.Tunisia market size and forecast, by therapeutic class
9.6.10.Algeria
9.6.10.1.Algeria market size and forecast, by indication
9.6.10.2.Algeria market size and forecast, by type
9.6.10.3.Algeria market size and forecast, by dosage form
9.6.10.4.Algeria market size and forecast, by distribution channel
9.6.10.5.Algeria market size and forecast, by therapeutic class
9.6.11.Lybia
9.6.11.1.Lybia market size and forecast, by indication
9.6.11.2.Lybia market size and forecast, by type
9.6.11.3.Lybia market size and forecast, by dosage form
9.6.11.4.Lybia market size and forecast, by distribution channel
9.6.11.5.Lybia market size and forecast, by therapeutic class
9.6.12.Rest of North Africa
9.6.12.1.Rest of North Africa market size and forecast, by indication
9.6.12.2.Rest of North Africa market size and forecast, by type
9.6.12.3.Rest of North Africa market size and forecast, by dosage form
9.6.12.4.Rest of North Africa market size and forecast, by distribution channel
9.6.12.5.Rest of North Africa market size and forecast, by therapeutic class
9.7.Rest of world
9.7.1.Rest of the World market size and forecast, by indication
9.7.2.Rest of the World market size and forecast, by type
9.7.3.Rest of the World market size and forecast, by dosage form
9.7.4.Rest of the World market size and forecast, by distribution channel
9.7.5.Rest of the World market size and forecast, by therapeutic class
9.7.6.Rest of the World market size and forecast, by country
9.7.7.Brazil
9.7.7.1.Brazil market size and forecast, by indication
9.7.7.2.Brazil market size and forecast, by type
9.7.7.3.Brazil market size and forecast, by dosage form
9.7.7.4.Brazil market size and forecast, by distribution channel
9.7.7.5.Brazil market size and forecast, by therapeutic class
9.7.8.Others
9.7.8.1.Others market size and forecast, by indication
9.7.8.2.Others market size and forecast, by type
9.7.8.3.Others market size and forecast, by dosage form
9.7.8.4.Others market size and forecast, by distribution channel
9.7.8.5.Others market size and forecast, by therapeutic class
CHAPTER 10:COMPANY PROFILES
10.1.ABBVIE Inc. (ALLERGAN PLC)
10.1.1.Company overview
10.1.2.Company snapshot
10.1.3.Operating business segments
10.1.4.Product portfolio
10.1.5.Business performance
10.1.6.Key strategic moves and developments
10.2.Alcon, Inc.
10.2.1.Company overview
10.2.2.Company snapshot
10.2.3.Operating business segments
10.2.4.Product portfolio
10.2.5.Business performance
10.2.6.Key strategic moves and developments
10.3.BAUSCH & LOMB INCORPORATED
10.3.1.Company overview
10.3.2.Company snapshot
10.3.3.Operating business segments
10.3.4.Product portfolio
10.3.5.Business performance
10.3.6.Key strategic moves and developments
10.4.F. HOFFMANN-LA ROCHE LTD (GENENTECH, INC.)
10.4.1.Company overview
10.4.2.Company snapshot
10.4.3.Operating business segments
10.4.4.Product portfolio
10.4.5.Business performance
10.4.6.Key strategic moves and developments
10.5.NOVARTIS AG
10.5.1.Company overview
10.5.2.Company snapshot
10.5.3.Operating business segments
10.5.4.Product portfolio
10.5.5.Business performance
10.5.6.Key strategic moves and developments
10.6.PFIZER INC.
10.6.1.Company overview
10.6.2.Company snapshot
10.6.3.Operating business segments
10.6.4.Product portfolio
10.6.5.Business performance
10.6.6.Key strategic moves and developments
10.7.REGENERON PHARMACEUTICALS INC.
10.7.1.Company overview
10.7.2.Company snapshot
10.7.3.Product portfolio
10.7.4.Business performance
10.7.5.Key strategic moves and developments
10.8.SANTEN PHARMACEUTICAL CO., LTD
10.8.1.Company overview
10.8.2.Company snapshot
10.8.3.Operating business segments
10.8.4.Product portfolio
10.8.5.Business performance
10.8.6.Key strategic moves and developments
10.9.SUN PHARMACEUTICAL INDUSTRIES LIMITED
10.9.1.Company overview
10.9.2.Company snapshot
10.9.3.Operating business segments
10.9.4.Product portfolio
10.9.5.Business performance
10.9.6.Key strategic moves and developments
10.10.TEVA PHARMACEUTICAL INDUSTRIES LTD. (ACTAVIS GENERICS)
10.10.1.Company overview
10.10.2.Company snapshot
10.10.3.Operating business segments
10.10.4.Product portfolio
10.10.5.Business performance
10.10.6.Key strategic moves and developments
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Top player positioning, 2019
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in prevalence of ophthalmic disorders
3.5.1.2.Advancements in research and development in optometry
3.5.1.3.Growth in geriatric population
3.5.1.4.Increase in demand for the ophthalmic drugs
3.5.2.Restraints
3.5.2.1.Risks associated with ophthalmic drugs
3.5.2.2.Longer timeline required for the formulation of ophthalmic drugs
3.5.3.Opportunity
3.5.3.1.Increase in research and developments by major key players
3.5.4.Impact analysis
3.6.Impact analysis of COVID-19 on the Ophthalmic Drug market
CHAPTER 4:OPHTHALMIC DRUGS MARKET, BY INDICATION
4.1.Overview
4.1.1.Market size and forecast
4.2.Dry Eye
4.2.1.Market size and forecast, by region
4.2.2.Market analysis, by country
4.2.3.Market size and forecast, by dosage form
4.3.Glaucoma
4.3.1.Market size and forecast, by region
4.3.2.Market analysis, by country
4.3.3.Market size and forecast, by dosage form
4.4.Infection/Inflammation/Allergy
4.4.1.Market size and forecast, by region
4.4.2.Market analysis, by country
4.4.3.Market size and forecast, by dosage form
4.5.Retinal Disorders
4.5.1.Market size and forecast, by type
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
4.5.4.Market size and forecast, by dosage form
4.5.5.Wet age-related macular degeneration
4.5.5.1.Market size and forecast, by dosage form
4.5.6.Dry age-related macular degeneration
4.5.6.1.Market size and forecast, by dosage form
4.5.7.Diabetic retinopathy
4.5.7.1.Market size and forecast, by dosage form
4.5.8.Other Retinal Disorders
4.5.8.1.Market size and forecast, by dosage form
4.6.Others
4.6.1.Market size and forecast, by region
4.6.2.Market analysis, by country
4.6.3.Market size and forecast, by dosage form
CHAPTER 5:OPHTHALMIC DRUGS MARKET, BY TYPE
5.1.Overview
5.1.1.Market size and forecast
5.2.Prescription Drugs
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.2.3.Market size and forecast, by dosage form
5.3.Over-The-Counter-Drugs
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.3.3.Market size and forecast, by dosage form
CHAPTER 6:OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM
6.1.Overview
6.1.1.Market size and forecast
6.2.Liquid ophthalmic drug forms
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Solid ophthalmic drug forms
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Semisolid ophthalmic drug forms
6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country
6.5.Multicompartment drug delivery systems
6.5.1.Market size and forecast, by region
6.5.2.Market analysis, by country
6.6.Other ophthalmic drug forms
6.6.1.Market size and forecast, by region
6.6.2.Market analysis, by country
6.7.Dry Eye
6.7.1.Market size and forecast, by region
6.7.2.Market analysis, by country
6.7.3.Market size and forecast, by dosage form
6.8.Glaucoma
6.8.1.Market size and forecast, by region
6.8.2.Market analysis, by country
6.8.3.Market size and forecast, by dosage form
6.9.Infection/Inflammation/Allergy
6.9.1.Market size and forecast, by region
6.9.2.Market analysis, by country
6.9.3.Market size and forecast, by dosage form
6.10.Retinal Disorders
6.10.1.Market size and forecast, by type
6.10.2.Market size and forecast, by region
6.10.3.Market analysis, by country
6.10.4.Market size and forecast, by dosage form
6.10.5.Wet age-related macular degeneration
6.10.5.1.Market size and forecast, by dosage form
6.10.6.Dry age-related macular degeneration
6.10.6.1.Market size and forecast, by dosage form
6.10.7.Diabetic retinopathy
6.10.7.1.Market size and forecast, by dosage form
6.10.8.Other Retinal Disorders
6.10.8.1.Market size and forecast, by dosage form
6.11.Others
6.11.1.Market size and forecast, by region
6.11.2.Market analysis, by country
6.11.3.Market size and forecast, by dosage form
CHAPTER 7:OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
7.1.Overview
7.1.1.Market size and forecast
7.2.Hospital Pharmacies
7.2.1.Market size and forecast, by region
7.2.2.Market analysis, by country
7.2.3.Market size and forecast, by dosage form
7.3.Drug Stores
7.3.1.Market size and forecast, by region
7.3.2.Market analysis, by country
7.3.3.Market size and forecast, by dosage form
7.4.Online Pharmacies
7.4.1.Market size and forecast, by region
7.4.2.Market analysis, by country
7.4.3.Market size and forecast, by dosage form
7.5.Others
7.5.1.Market size and forecast, by region
7.5.2.Market analysis, by country
7.5.3.Market size and forecast, by dosage form
CHAPTER 8:OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS
8.1.Overview
8.1.1.Market size and forecast
8.2.Anti-Glaucoma
8.2.1.Market size and forecast, by region
8.2.2.Market analysis, by country
8.2.3.Market size and forecast, by dosage form
8.3.Anti-infection
8.3.1.Market size and forecast, by region
8.3.2.Market analysis, by country
8.3.3.Market size and forecast, by dosage form
8.4.Anti-inflammatory
8.4.1.Market size and forecast, by region
8.4.2.Market analysis, by country
8.4.3.Market size and forecast, by dosage form
8.5.Anti-allergy
8.5.1.Market size and forecast, by region
8.5.2.Market analysis, by country
8.5.3.Market size and forecast, by dosage form
8.6.Others
8.6.1.Market size and forecast, by region
8.6.2.Market analysis, by country
8.6.3.Market size and forecast, by dosage form
CHAPTER 9:OPHTHALMIC DRUGS MARKET, BY REGION
9.1.Overview
9.1.1.Market size and forecast
9.2.North America
9.2.1.North America market size and forecast, by indication
9.2.2.North America market size and forecast, by type
9.2.3.North America market size and forecast, by dosage form
9.2.4.North America market size and forecast, by distribution channel
9.2.5.North America market size and forecast, by therapeutic class
9.2.6.North America market size and forecast, by country
9.2.7.U.S.
9.2.7.1.U.S. market size and forecast, by indication
9.2.7.2.U.S. market size and forecast, by type
9.2.7.3.U.S. market size and forecast, by dosage form
9.2.7.4.U.S. market size and forecast, by distribution channel
9.2.7.5.U.S. market size and forecast, by therapeutic class
9.2.8.Rest of North America
9.2.8.1.Rest of North America market size and forecast, by indication
9.2.8.2.Rest of North America market size and forecast, by type
9.2.8.3.Rest of North America market size and forecast, by dosage form
9.2.8.4.Rest of North America market size and forecast, by distribution channel
9.2.8.5.Rest of North America market size and forecast, by therapeutic class
9.3.Europe
9.3.1.Europe market size and forecast, by indication
9.3.2.Europe market size and forecast, by type
9.3.3.Europe market size and forecast, by dosage form
9.3.4.Europe market size and forecast, by distribution channel
9.3.5.Europe market size and forecast, by therapeutic class
9.3.6.Europe market size and forecast, by country
9.3.7.Germany
9.3.7.1.Germany market size and forecast, by indication
9.3.7.2.Germany market size and forecast, by type
9.3.7.3.Germany market size and forecast, by dosage form
9.3.7.4.Germany market size and forecast, by distribution channel
9.3.7.5.Germany market size and forecast, by therapeutic class
9.3.8.France
9.3.8.1.France market size and forecast, by indication
9.3.8.2.France market size and forecast, by type
9.3.8.3.France market size and forecast, by dosage form
9.3.8.4.France market size and forecast, by distribution channel
9.3.8.5.France market size and forecast, by therapeutic class
9.3.9.UK
9.3.9.1.UK market size and forecast, by indication
9.3.9.2.UK market size and forecast, by type
9.3.9.3.UK market size and forecast, by dosage form
9.3.9.4.UK market size and forecast, by distribution channel
9.3.9.5.UK market size and forecast, by therapeutic class
9.3.10.Italy
9.3.10.1.Italy market size and forecast, by indication
9.3.10.2.Italy market size and forecast, by type
9.3.10.3.Italy market size and forecast, by dosage form
9.3.10.4.Italy market size and forecast, by distribution channel
9.3.10.5.Italy market size and forecast, by therapeutic class
9.3.11.Spain
9.3.11.1.Spain market size and forecast, by indication
9.3.11.2.Spain market size and forecast, by type
9.3.11.3.Spain market size and forecast, by dosage form
9.3.11.4.Spain market size and forecast, by distribution channel
9.3.11.5.Spain market size and forecast, by therapeutic class
9.3.12.Poland
9.3.12.1.Poland market size and forecast, by indication
9.3.12.2.Poland market size and forecast, by type
9.3.12.3.Poland market size and forecast, by dosage form
9.3.12.4.Poland market size and forecast, by distribution channel
9.3.12.5.Poland market size and forecast, by therapeutic class
9.3.13.Rest of Europe
9.3.13.1.Rest of Europe market size and forecast, by indication
9.3.13.2.Rest of Europe market size and forecast, by type
9.3.13.3.Rest of Europe market size and forecast, by dosage form
9.3.13.4.Rest of Europe market size and forecast, by distribution channel
9.3.13.5.Rest of Europe market size and forecast, by therapeutic class
9.4.Asia-Pacific
9.4.1.Asia-Pacific market size and forecast, by indication
9.4.2.Asia-Pacific market size and forecast, by type
9.4.3.Asia-Pacific market size and forecast, by dosage form
9.4.4.Asia-Pacific market size and forecast, by distribution channel
9.4.5.Asia-Pacific market size and forecast, by therapeutic class
9.4.6.Asia-Pacific market size and forecast, by country
9.4.7.Malaysia
9.4.7.1.Malaysia market size and forecast, by indication
9.4.7.2.Malaysia market size and forecast, by type
9.4.7.3.Malaysia market size and forecast, by dosage form
9.4.7.4.Malaysia market size and forecast, by distribution channel
9.4.7.5.Malaysia market size and forecast, by therapeutic class
9.4.8.Vietnam
9.4.8.1.Vietnam market size and forecast, by indication
9.4.8.2.Vietnam market size and forecast, by type
9.4.8.3.Vietnam market size and forecast, by dosage form
9.4.8.4.Vietnam market size and forecast, by distribution channel
9.4.8.5.Vietnam market size and forecast, by therapeutic class
9.4.9.Thailand
9.4.9.1.Thailand market size and forecast, by indication
9.4.9.2.Thailand market size and forecast, by type
9.4.9.3.Thailand market size and forecast, by dosage form
9.4.9.4.Thailand market size and forecast, by distribution channel
9.4.9.5.Thailand market size and forecast, by therapeutic class
9.4.10.Philippines
9.4.10.1.Philippines market size and forecast, by indication
9.4.10.2.Philippines market size and forecast, by type
9.4.10.3.Philippines market size and forecast, by dosage form
9.4.10.4.Philippines market size and forecast, by distribution channel
9.4.10.5.Philippines market size and forecast, by therapeutic class
9.4.11.Rest of Asia-Pacific
9.4.11.1.Rest of Asia-Pacific market size and forecast, by indication
9.4.11.2.Rest of Asia-Pacific market size and forecast, by type
9.4.11.3.Rest of Asia-Pacific market size and forecast, by dosage form
9.4.11.4.Rest of Asia-Pacific market size and forecast, by distribution channel
9.4.11.5.Rest of Asia-Pacific market size and forecast, by therapeutic class
9.5.Middle East
9.5.1.Middle East market size and forecast, by indication
9.5.2.Middle East market size and forecast, by type
9.5.3.Middle East market size and forecast, by dosage form
9.5.4.Middle East market size and forecast, by distribution channel
9.5.5.Middle East market size and forecast, by therapeutic class
9.5.6.Middle East market size and forecast, by country
9.5.7.UAE
9.5.7.1.UAE market size and forecast, by indication
9.5.7.2.UAE market size and forecast, by type
9.5.7.3.UAE market size and forecast, by dosage form
9.5.7.4.UAE market size and forecast, by distribution channel
9.5.7.5.UAE market size and forecast, by therapeutic class
9.5.8.Saudi Arabia
9.5.8.1.Saudi Arabia market size and forecast, by indication
9.5.8.2.Saudi Arabia market size and forecast, by type
9.5.8.3.Saudi Arabia market size and forecast, by dosage form
9.5.8.4.Saudi Arabia market size and forecast, by distribution channel
9.5.8.5.Saudi Arabia market size and forecast, by therapeutic class
9.5.9.Palestine
9.5.9.1.Palestine market size and forecast, by indication
9.5.9.2.Palestine market size and forecast, by type
9.5.9.3.Palestine market size and forecast, by dosage form
9.5.9.4.Palestine market size and forecast, by distribution channel
9.5.9.5.Palestine market size and forecast, by therapeutic class
9.5.10.Jordan
9.5.10.1.Jordan market size and forecast, by indication
9.5.10.2.Jordan market size and forecast, by type
9.5.10.3.Jordan market size and forecast, by dosage form
9.5.10.4.Jordan market size and forecast, by distribution channel
9.5.10.5.Jordan market size and forecast, by therapeutic class
9.5.11.Bahrain
9.5.11.1.Bahrain market size and forecast, by indication
9.5.11.2.Bahrain market size and forecast, by type
9.5.11.3.Bahrain market size and forecast, by dosage form
9.5.11.4.Bahrain market size and forecast, by distribution channel
9.5.11.5.Bahrain market size and forecast, by therapeutic class
9.5.12.Qatar
9.5.12.1.Qatar market size and forecast, by indication
9.5.12.2.Qatar market size and forecast, by type
9.5.12.3.Qatar market size and forecast, by dosage form
9.5.12.4.Qatar market size and forecast, by distribution channel
9.5.12.5.Qatar market size and forecast, by therapeutic class
9.5.13.Azerbaijan
9.5.13.1.Azerbaijan market size and forecast, by indication
9.5.13.2.Azerbaijan market size and forecast, by type
9.5.13.3.Azerbaijan market size and forecast, by dosage form
9.5.13.4.Azerbaijan market size and forecast, by distribution channel
9.5.13.5.Azerbaijan market size and forecast, by therapeutic class
9.5.14.Georgia
9.5.14.1.Georgia market size and forecast, by indication
9.5.14.2.Georgia market size and forecast, by type
9.5.14.3.Georgia market size and forecast, by dosage form
9.5.14.4.Georgia market size and forecast, by distribution channel
9.5.14.5.Georgia market size and forecast, by therapeutic class
9.5.15.Iraq
9.5.15.1.Iraq market size and forecast, by indication
9.5.15.2.Iraq market size and forecast, by type
9.5.15.3.Iraq market size and forecast, by dosage form
9.5.15.4.Iraq market size and forecast, by distribution channel
9.5.15.5.Iraq market size and forecast, by therapeutic class
9.5.16.Pakistan
9.5.16.1.Pakistan market size and forecast, by indication
9.5.16.2.Pakistan market size and forecast, by type
9.5.16.3.Pakistan market size and forecast, by dosage form
9.5.16.4.Pakistan market size and forecast, by distribution channel
9.5.16.5.Pakistan market size and forecast, by therapeutic class
9.5.17.Kuwait
9.5.17.1.Kuwait market size and forecast, by indication
9.5.17.2.Kuwait market size and forecast, by type
9.5.17.3.Kuwait market size and forecast, by dosage form
9.5.17.4.Kuwait market size and forecast, by distribution channel
9.5.17.5.Kuwait market size and forecast, by therapeutic class
9.5.18.Israel
9.5.18.1.Israel market size and forecast, by indication
9.5.18.2.Israel market size and forecast, by type
9.5.18.3.Israel market size and forecast, by dosage form
9.5.18.4.Israel market size and forecast, by distribution channel
9.5.18.5.Israel market size and forecast, by therapeutic class
9.5.19.Kazakhstan
9.5.19.1.Kazakhstan market size and forecast, by indication
9.5.19.2.Kazakhstan market size and forecast, by type
9.5.19.3.Kazakhstan market size and forecast, by dosage form
9.5.19.4.Kazakhstan market size and forecast, by distribution channel
9.5.19.5.Kazakhstan market size and forecast, by therapeutic class
9.5.20.Uzbekistan
9.5.20.1.Uzbekistan market size and forecast, by indication
9.5.20.2.Uzbekistan market size and forecast, by type
9.5.20.3.Uzbekistan market size and forecast, by dosage form
9.5.20.4.Uzbekistan market size and forecast, by distribution channel
9.5.20.5.Uzbekistan market size and forecast, by therapeutic class
9.5.21.Tajikistan
9.5.21.1.Tajikistan market size and forecast, by indication
9.5.21.2.Tajikistan market size and forecast, by type
9.5.21.3.Tajikistan market size and forecast, by dosage form
9.5.21.4.Tajikistan market size and forecast, by distribution channel
9.5.21.5.Tajikistan market size and forecast, by therapeutic class
9.5.22.Kyrgyzstan
9.5.22.1.Kyrgyzstan market size and forecast, by indication
9.5.22.2.Kyrgyzstan market size and forecast, by type
9.5.22.3.Kyrgyzstan market size and forecast, by dosage form
9.5.22.4.Kyrgyzstan market size and forecast, by distribution channel
9.5.22.5.Kyrgyzstan market size and forecast, by therapeutic class
9.5.23.Turkmenistan
9.5.23.1.Turkmenistan market size and forecast, by indication
9.5.23.2.Turkmenistan market size and forecast, by type
9.5.23.3.Turkmenistan market size and forecast, by dosage form
9.5.23.4.Turkmenistan market size and forecast, by distribution channel
9.5.23.5.Turkmenistan market size and forecast, by therapeutic class
9.5.24.Rest of Middle East
9.5.24.1.Rest of Middle East market size and forecast, by indication
9.5.24.2.Rest of Middle East market size and forecast, by type
9.5.24.3.Rest of Middle East market size and forecast, by dosage form
9.5.24.4.Rest of Middle East market size and forecast, by distribution channel
9.5.24.5.Rest of Middle East market size and forecast, by therapeutic class
9.6.North Africa
9.6.1.North Africa market size and forecast, by indication
9.6.2.North Africa market size and forecast, by type
9.6.3.North Africa market size and forecast, by dosage form
9.6.4.North Africa market size and forecast, by distribution channel
9.6.5.North Africa market size and forecast, by therapeutic class
9.6.6.North Africa market size and forecast, by country
9.6.7.Egypt
9.6.7.1.Egypt market size and forecast, by indication
9.6.7.2.Egypt market size and forecast, by type
9.6.7.3.Egypt market size and forecast, by dosage form
9.6.7.4.Egypt market size and forecast, by distribution channel
9.6.7.5.Egypt market size and forecast, by therapeutic class
9.6.8.Morocco
9.6.8.1.Morocco market size and forecast, by indication
9.6.8.2.Morocco market size and forecast, by type
9.6.8.3.Morocco market size and forecast, by dosage form
9.6.8.4.Morocco market size and forecast, by distribution channel
9.6.8.5.Morocco market size and forecast, by therapeutic class
9.6.9.Tunisia
9.6.9.1.Tunisia market size and forecast, by indication
9.6.9.2.Tunisia market size and forecast, by type
9.6.9.3.Tunisia market size and forecast, by dosage form
9.6.9.4.Tunisia market size and forecast, by distribution channel
9.6.9.5.Tunisia market size and forecast, by therapeutic class
9.6.10.Algeria
9.6.10.1.Algeria market size and forecast, by indication
9.6.10.2.Algeria market size and forecast, by type
9.6.10.3.Algeria market size and forecast, by dosage form
9.6.10.4.Algeria market size and forecast, by distribution channel
9.6.10.5.Algeria market size and forecast, by therapeutic class
9.6.11.Lybia
9.6.11.1.Lybia market size and forecast, by indication
9.6.11.2.Lybia market size and forecast, by type
9.6.11.3.Lybia market size and forecast, by dosage form
9.6.11.4.Lybia market size and forecast, by distribution channel
9.6.11.5.Lybia market size and forecast, by therapeutic class
9.6.12.Rest of North Africa
9.6.12.1.Rest of North Africa market size and forecast, by indication
9.6.12.2.Rest of North Africa market size and forecast, by type
9.6.12.3.Rest of North Africa market size and forecast, by dosage form
9.6.12.4.Rest of North Africa market size and forecast, by distribution channel
9.6.12.5.Rest of North Africa market size and forecast, by therapeutic class
9.7.Rest of world
9.7.1.Rest of the World market size and forecast, by indication
9.7.2.Rest of the World market size and forecast, by type
9.7.3.Rest of the World market size and forecast, by dosage form
9.7.4.Rest of the World market size and forecast, by distribution channel
9.7.5.Rest of the World market size and forecast, by therapeutic class
9.7.6.Rest of the World market size and forecast, by country
9.7.7.Brazil
9.7.7.1.Brazil market size and forecast, by indication
9.7.7.2.Brazil market size and forecast, by type
9.7.7.3.Brazil market size and forecast, by dosage form
9.7.7.4.Brazil market size and forecast, by distribution channel
9.7.7.5.Brazil market size and forecast, by therapeutic class
9.7.8.Others
9.7.8.1.Others market size and forecast, by indication
9.7.8.2.Others market size and forecast, by type
9.7.8.3.Others market size and forecast, by dosage form
9.7.8.4.Others market size and forecast, by distribution channel
9.7.8.5.Others market size and forecast, by therapeutic class
CHAPTER 10:COMPANY PROFILES
10.1.ABBVIE Inc. (ALLERGAN PLC)
10.1.1.Company overview
10.1.2.Company snapshot
10.1.3.Operating business segments
10.1.4.Product portfolio
10.1.5.Business performance
10.1.6.Key strategic moves and developments
10.2.Alcon, Inc.
10.2.1.Company overview
10.2.2.Company snapshot
10.2.3.Operating business segments
10.2.4.Product portfolio
10.2.5.Business performance
10.2.6.Key strategic moves and developments
10.3.BAUSCH & LOMB INCORPORATED
10.3.1.Company overview
10.3.2.Company snapshot
10.3.3.Operating business segments
10.3.4.Product portfolio
10.3.5.Business performance
10.3.6.Key strategic moves and developments
10.4.F. HOFFMANN-LA ROCHE LTD (GENENTECH, INC.)
10.4.1.Company overview
10.4.2.Company snapshot
10.4.3.Operating business segments
10.4.4.Product portfolio
10.4.5.Business performance
10.4.6.Key strategic moves and developments
10.5.NOVARTIS AG
10.5.1.Company overview
10.5.2.Company snapshot
10.5.3.Operating business segments
10.5.4.Product portfolio
10.5.5.Business performance
10.5.6.Key strategic moves and developments
10.6.PFIZER INC.
10.6.1.Company overview
10.6.2.Company snapshot
10.6.3.Operating business segments
10.6.4.Product portfolio
10.6.5.Business performance
10.6.6.Key strategic moves and developments
10.7.REGENERON PHARMACEUTICALS INC.
10.7.1.Company overview
10.7.2.Company snapshot
10.7.3.Product portfolio
10.7.4.Business performance
10.7.5.Key strategic moves and developments
10.8.SANTEN PHARMACEUTICAL CO., LTD
10.8.1.Company overview
10.8.2.Company snapshot
10.8.3.Operating business segments
10.8.4.Product portfolio
10.8.5.Business performance
10.8.6.Key strategic moves and developments
10.9.SUN PHARMACEUTICAL INDUSTRIES LIMITED
10.9.1.Company overview
10.9.2.Company snapshot
10.9.3.Operating business segments
10.9.4.Product portfolio
10.9.5.Business performance
10.9.6.Key strategic moves and developments
10.10.TEVA PHARMACEUTICAL INDUSTRIES LTD. (ACTAVIS GENERICS)
10.10.1.Company overview
10.10.2.Company snapshot
10.10.3.Operating business segments
10.10.4.Product portfolio
10.10.5.Business performance
10.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.GLOBAL OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 02.GLOBAL OPHTHALMIC DRUGS MARKET FOR DRY EYE, BY REGION, 2019–2027 ($MILLION)
TABLE 03.GLOBAL OPHTHALMIC DRUGS MARKET FOR DRY EYE, BY DOSAGE FORM, 2019–2027 ($MILLION)
TABLE 04.GLOBAL OPHTHALMIC DRUGS MARKET FOR GLAUCOMA, BY REGION, 2019–2027 ($MILLION)
TABLE 05.GLOBAL OPHTHALMIC DRUGS MARKET FOR GLAUCOMA, BY DOSAGE FORM, 2019–2027 ($MILLION)
TABLE 06.GLOBAL OPHTHALMIC DRUGS MARKET FOR INFECTION/INFLAMMATION/ALLERGY, BY REGION, 2019–2027 ($MILLION)
TABLE 07.GLOBAL OPHTHALMIC DRUGS MARKET FOR INFECTION/INFLAMMATION/ALLERGY, BY DOSAGE FORM, 2019–2027 ($MILLION)
TABLE 08.GLOBAL OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY TYPE, 2019–2027 ($MILLION)
TABLE 09.GLOBAL OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY REGION, 2019–2027 ($MILLION)
TABLE 10.GLOBAL OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY DOSAGE FORM, 2019–202
TABLE 01.GLOBAL OPHTHALMIC DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 02.GLOBAL OPHTHALMIC DRUGS MARKET FOR DRY EYE, BY REGION, 2019–2027 ($MILLION)
TABLE 03.GLOBAL OPHTHALMIC DRUGS MARKET FOR DRY EYE, BY DOSAGE FORM, 2019–2027 ($MILLION)
TABLE 04.GLOBAL OPHTHALMIC DRUGS MARKET FOR GLAUCOMA, BY REGION, 2019–2027 ($MILLION)
TABLE 05.GLOBAL OPHTHALMIC DRUGS MARKET FOR GLAUCOMA, BY DOSAGE FORM, 2019–2027 ($MILLION)
TABLE 06.GLOBAL OPHTHALMIC DRUGS MARKET FOR INFECTION/INFLAMMATION/ALLERGY, BY REGION, 2019–2027 ($MILLION)
TABLE 07.GLOBAL OPHTHALMIC DRUGS MARKET FOR INFECTION/INFLAMMATION/ALLERGY, BY DOSAGE FORM, 2019–2027 ($MILLION)
TABLE 08.GLOBAL OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY TYPE, 2019–2027 ($MILLION)
TABLE 09.GLOBAL OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY REGION, 2019–2027 ($MILLION)
TABLE 10.GLOBAL OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY DOSAGE FORM, 2019–202
